<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646828</url>
  </required_header>
  <id_info>
    <org_study_id>P070139</org_study_id>
    <nct_id>NCT00646828</nct_id>
  </id_info>
  <brief_title>Cardiovascular Evaluation of Adult PHA 1 Patients</brief_title>
  <acronym>PHACARV</acronym>
  <official_title>Cardiovascular Evaluation of a Rare Condition With Hyperaldosteronism Without Hypertension: PHA 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular and cardiac alterations are associated with aldosterone effects are evidenced in
      experimental models and aldosterone receptor blockade is of clear benefit in cardiac disease
      (heart failure). The study aims at assessing vascular and cardiac alterations in adults with
      a chronic increase in circulating aldosterone without hypertension. The investigated
      population will be patients with a rare disease, pseudohypoaldosteronism type 1, due to
      heterozygous inactivating mutations of the mineralocorticoid receptor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes adult patients with mineralocorticoid receptor mutation as compared with
      not affected relatives. It includes also relatives of adult relative of patients with PHA1 in
      whom no mutation was found. Cardiovascular evaluation is conducted with cardiac and vascular
      ultrasound assessment and cardiac NMR, ambulatory blood pressure measurement.

      Protocol duration is 2 days . Detailed genetic study is conducted in family without
      identified mutation in MINERALORECEPTOR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac or vascular abnormality at ultrasound or NMR evaluation</measure>
    <time_frame>day one</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracellular volume, biology, autonomic nervous system abnormality</measure>
    <time_frame>day one + day two</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New gene responsible for PHA1</measure>
    <time_frame>day one</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Pseudohypoaldosteronism Type 1</condition>
  <arm_group>
    <arm_group_label>without PHA1</arm_group_label>
    <description>patients without mineralocorticoid receptor mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHA 1</arm_group_label>
    <description>patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patient with Pseudohypoaldosteronism type 1 and the family of these patient who dont have
        mineralocorticoid receptor mutation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age over 18

          -  Male or female gender

          -  Genotype in the PHA1.NET network

        Exclusion criteria:

          -  Not membership to a regime of Social Security or to a CMU

          -  Against indication in the realization of a MRI

          -  Cardiac NMR not possible

          -  Known cardiovascular disease for person not carrying MR mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte ESCOUBET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pujo L, Fagart J, Gary F, Papadimitriou DT, Claës A, Jeunemaître X, Zennaro MC. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat. 2007 Jan;28(1):33-40.</citation>
    <PMID>16972228</PMID>
  </reference>
  <reference>
    <citation>Sacré K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, Lidove O, Laissy JP, Papo T. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum. 2010 Jul;62(7):2093-100. doi: 10.1002/art.27488.</citation>
    <PMID>20506512</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pseudohypoaldosteronism type 1</keyword>
  <keyword>Mineralocorticoid receptor</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

